Barclays
NVO

Barclays’s Novo Nordisk NVO Stock Holding History

Barclays’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-300
Closed -$15.3K – 5311
2025
Q4 		$15.3K Sell
300
-916,500
-100% -$46.9M ﹤0.01% 4897
2025
Q3 		$50.9M Buy
916,800
+841,500
+1,118% +$49.3M 0.01% 759
2025
Q2 		$5.2M Buy
75,300
+29,100
+63% +$1.98M ﹤0.01% 2094
2025
Q1 		$3.21M Buy
46,200
+35,500
+332% +$2.93M ﹤0.01% 2271
2024
Q4 		$920K Buy
+10,700
New +$1.16M ﹤0.01% 3429
2024
Q3 		– Sell
-370,000
Closed -$52.8M – 5419
2024
Q2 		$52.8M Buy
+370,000
New +$49M 0.02% 601
2023
Q1 		– Sell
-215,000
Closed -$14.5M – 5269
2022
Q4 		$14.5M Buy
+215,000
New +$12.6M 0.01% 1031
2020
Q2 		– Sell
-36,400
Closed -$1.1M – 6055
2020
Q1 		$1.1M Sell
36,400
-78,200
-68% -$2.33M ﹤0.01% 2857
2019
Q4 		$3.32M Sell
114,600
-24,600
-18% -$681K ﹤0.01% 2452
2019
Q3 		$3.6M Buy
139,200
+64,400
+86% +$1.63M ﹤0.01% 2177
2019
Q2 		$1.91M Buy
74,800
+4,400
+6% +$109K ﹤0.01% 2974
2019
Q1 		$1.84M Sell
70,400
-38,000
-35% -$934K ﹤0.01% 2662
2018
Q4 		$2.5M Buy
108,400
+33,200
+44% +$738K ﹤0.01% 2177
2018
Q3 		$1.77M Sell
75,200
-30,200
-29% -$737K ﹤0.01% 3024
2018
Q2 		$2.43M Sell
105,400
-620,600
-85% -$14.7M ﹤0.01% 2381
2018
Q1 		$17.9M Buy
726,000
+641,000
+754% +$16.8M 0.01% 907
2017
Q4 		$2.28M Sell
85,000
-59,200
-41% -$1.51M ﹤0.01% 2308
2017
Q3 		$3.47M Sell
144,200
-168,800
-54% -$3.81M ﹤0.01% 1823
2017
Q2 		$6.71M Buy
313,000
+277,400
+779% +$5.6M 0.01% 1252
2017
Q1 		$610K Sell
35,600
-10,200
-22% -$178K ﹤0.01% 3209
2016
Q4 		$821K Buy
45,800
+15,400
+51% +$279K ﹤0.01% 2940
2016
Q3 		$632K Buy
30,400
+7,400
+32% +$183K ﹤0.01% 3033
2016
Q2 		$618K Buy
23,000
+19,800
+619% +$543K ﹤0.01% 3029
2016
Q1 		$86K Sell
3,200
-18,000
-85% -$482K ﹤0.01% 4454
2015
Q4 		$615K Sell
21,200
-11,000
-34% -$304K ﹤0.01% 3042
2015
Q3 		$869K Buy
32,200
+26,800
+496% +$759K ﹤0.01% 2866
2015
Q2 		$146K Buy
5,400
+1,600
+42% +$45K ﹤0.01% 4382
2015
Q1 		$101K Sell
3,800
-7,400
-66% -$170K ﹤0.01% 4844
2014
Q4 		$235K Buy
11,200
+1,200
+12% +$26.8K ﹤0.01% 4512
2014
Q3 		$235K Sell
10,000
-13,000
-57% -$299K ﹤0.01% 4599
2014
Q2 		$529K Sell
23,000
-1,600
-7% -$35.3K ﹤0.01% 3924
2014
Q1 		$554K Sell
24,600
-16,400
-40% -$349K ﹤0.01% 3855
2013
Q4 		$754K Buy
41,000
+14,000
+52% +$244K ﹤0.01% 3695
2013
Q3 		$456K Sell
27,000
-64,000
-70% -$1.08M ﹤0.01% 4211
2013
Q2 		$1.41M Buy
+91,000
New +$1.51M ﹤0.01% 2941

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Barclays's NVO Position: Q1 2026 in Review

Barclays increased its Novo Nordisk (NVO) stake by 246% in Q1 2026, buying an estimated $111M and bringing the position to 3,283,636 shares worth $121M. The position accounts for 0.03% of the portfolio, ranked #437.

Barclays first reported a position in NVO in Q2 2013 and has held it in 51 quarters since. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Barclays held 3,283,636 shares of Novo Nordisk worth $121M as of Q1 2026.
  • Barclays bought 2,333,364 Novo Nordisk shares in Q1 2026, an estimated $111M.
  • Novo Nordisk made up 0.03% of Barclays's portfolio in Q1 2026, its #437 holding.
  • Barclays first reported a position in Novo Nordisk in Q2 2013 and has held it in 51 quarters since.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.